Management of Erythrocytosis in Men Receiving Testosterone Therapy: Clinical Consultation Guide

Pranjal Agrawal; Sajya M Singh; Taylor Kohn

doi:10.1016/j.euf.2022.10.008

Management of Erythrocytosis in Men Receiving Testosterone Therapy: Clinical Consultation Guide

Eur Urol Focus. 2023 Jan;9(1):20-21. doi: 10.1016/j.euf.2022.10.008. Epub 2022 Nov 2.

Authors

Pranjal Agrawal¹, Sajya M Singh¹, Taylor Kohn²

Affiliations

¹ Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: tpkohn@jhmi.edu.

PMID: 36335038
DOI: 10.1016/j.euf.2022.10.008

Abstract

The most common side effect of testosterone therapy (TT) is erythrocytosis. Patient-specific factors therefore should be considered when choosing an appropriate TT dosage and modality. Providers should decrease or discontinue therapy if the patient's hematocrit exceeds 54% until the hematocrit normalizes.

MeSH terms

Hematocrit
Humans
Male
Polycythemia* / chemically induced
Polycythemia* / drug therapy
Testosterone* / adverse effects

Substances

Testosterone